Integra LifeSciences Holdings Corporation provides revenue guidance for the second quarter of 2024. For the second quarter 2024, the Company expects reported revenues in the range of $411 million to $416 million, representing reported growth of 7.8% to 9.1% and organic growth of 1.3% to 2.6%.
Integra LifeSciences Holdings Corporation
Equities
IART
US4579852082
Medical Equipment, Supplies & Distribution
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
29.19 USD | +0.76% |
|
+1.28% | -32.97% |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-32.97% | 2.3B | |
-6.24% | 180B | |
-6.08% | 99.21B | |
-5.98% | 66.25B | |
-9.35% | 44.74B | |
+8.34% | 43.82B | |
+10.35% | 41.96B | |
+11.88% | 28.98B | |
+16.18% | 24.07B | |
-8.38% | 23.5B |
- Stock Market
- Equities
- IART Stock
- News Integra LifeSciences Holdings Corporation
- Integra LifeSciences Holdings Corporation Provides Revenue Guidance for the Second Quarter of 2024